-
Mashup Score: 2PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion - 1 year(s) ago
High-grade neuroendocrine tumors of the lung such as SCLC are recalcitrant cancers for which more effective systemic therapies are needed. Despite their histopathologic and molecular heterogeneity, they are generally treated as a single disease entity with similar chemotherapy regimens. Whereas marked clinical responses can be observed, they are short-lived. Inter- and intratumoral heterogeneity…
Source: Journal of Thoracic OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer - 1 year(s) ago
This study aimed to examine the value of PD-L1 copy number (CN) alteration as an additional biomarker to standard immunohistochemistry (IHC) in predicting response to immune checkpoint inhibitor (ICI) therapy in advanced NSCLC.
Source: Journal of Thoracic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Report that PD-L1 copy number loss has negative predictive value on top of PD-L1 IHC in patients with NSCLC receiving checkpoint inhibitors @JTOonline. https://t.co/FBi40QdMEi
-
-
Mashup Score: 4Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma - 1 year(s) ago
Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the potential value of multigene testing in early lung adenocarcinoma (LUAD).
Source: Journal of Thoracic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @AndresFCardonaZ: Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma https://t.co/TFYO8CxJLW
-
RT @AndresFCardonaZ: Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma https://t.co/TFYO8CxJLW
-
-
Mashup Score: 0
Sitravatinib, a receptor tyrosine kinase inhibitor targeting TYRO3, AXL, MERTK receptors, and vascular epithelial growth factor receptor 2, can shift the tumor microenvironment toward an immunostimulatory state. Combining sitravatinib with checkpoint inhibitors (CPIs) may augment antitumor activity.
Source: Journal of Thoracic OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of #sitravatinib w/checkpoint inhibitors (#CPI) demonstrates antitumor activity & encouraging survival in patients w/non-squamous #NSCLC experienced w/CPI. https://t.co/td3WaRhSQX #LCSM #PIIO @OSUCCC_James @OhioStateMed @OhioStateMedOnc @OhioStatePIIO @OSUWexMed https://t.co/Grfirn5OHH
-
-
Mashup Score: 0Analysis of serious weight gain in patients using alectinib for ALK positive lung cancer - 1 year(s) ago
Alectinib is a standard of care treatment for metastatic anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). Weight gain is an unexplored side effect reported in ∼10%. To prevent or intervene alectinib-induced weight gain, more insight in its extent and etiology is needed.
Source: Journal of Thoracic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Serious weight gain in pts w ALK+ NSCLC on Alectinib: - 46pts - weight/adiposity/muscle evaluated on CT - ⬆️sarcopenic obesity 23% to 47% at 1yr Survivorship needs may be changing w time &new therapies @Dingemans_AnneM @JTOonline #LCSM https://t.co/0OabY6VGnN
-
-
Mashup Score: 2
We explored the association of respiratory and cardiometabolic comorbidities with NSCLC overall survival (OS) and lung cancer-specific survival (LCSS), by stage, in a large, multicontinent NSCLC pooled data set.
Source: Journal of Thoracic OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A large, multi-continent #NSCLC pooled dataset reveals that either cardio metabolic or respiratory comorbidities are associated w/worse overall survival in Stage I-III NSCLC, among other results presented in this article: https://t.co/ZvFYMXz0EO @MiguelG_pds @pmcancercentre #LCSM https://t.co/OXbbmn8ImT
-
-
Mashup Score: 2
EMPOWER-Lung 3 Part 2 (NCT03409614), a double-blind, placebo-controlled phase 3 study, investigated cemiplimab (anti–PD-1) plus chemotherapy versus placebo plus chemotherapy in patients with advanced NSCLC without EGFR, ALK, or ROS1 aberrations, with either squamous or non-squamous histology, irrespective of PD-L1 levels. At primary analysis, after 16.4 months of follow-up, cemiplimab plus…
Source: Journal of Thoracic OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
EMPOWER-Lung 3: Pre-specified final OS analysis w/a 2-year follow-up shows a consistent benefit of #cemiplimab+ chemotherapy vs.chemotherapy alone in pts w/advanced squamous or non-squamous #NSCLC across PD-L1 levels https://t.co/MhWh3i3Fsn @myESMO #ELCC23 https://t.co/J2g2u6WcE9
-
-
Mashup Score: 2
Despite the unprecedented rapid advances in cancer therapeutics development, drug resistance remains a clinical challenge in precision oncology. Resistance is diverse at various levels with inter- and intra-tumor heterogeneity. Targeted therapy resistance can largely be categorized into three classes, including pathway reactivation (re-engagement of original effectors, aka “on-target”…
Source: Journal of Thoracic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
In @JTOonline, out an interesting editorial by @LeXiuning discussing the acquired resistance to EGFR inhibitors in #lungcancer, with focus on Fitness, Competition, and Diversity “Targeted therapy resistance can largely be categorized into three classes, https://t.co/rTrZG8pmcg… https://t.co/yTv9FjzbfB
-
-
Mashup Score: 0
Outcomes for patients with early stage non small cell lung cancer (NSCLC) remain dismal compared to other solid tumors. In the metastatic setting, immunotherapy has been the key driver of improved survival, but until recently, the role of immunotherapy in surgically resected NSCLC has been unclear. The IMpower010 study randomized 1280 patients with stage IB to IIIA NSCLC to either 1 year of the…
Source: Journal of Thoracic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
2/2 Excellent articles written by great experts. 1st article: Give to all patients with +PDL-1 👉 https://t.co/PloW7eV3Hs by @CharuAggarwalMD @MMarmarelis @LovaSunMD 2nd article: Give only to those with PDL-1 ≥ 50% 👉 https://t.co/O41bNkhh4N by @nicogirardcurie #LCSM https://t.co/SY0L8zrihu
-
-
Mashup Score: 1Selective Mediastinal Lymph Node Dissection Strategy for Clinical T1N0 Invasive Lung Cancer: A Prospective, Multicenter, Clinical Trial - 1 year(s) ago
We aimed to prospectively evaluate our previously proposed selective mediastinal lymph node (LN) dissection strategy for peripheral clinical T1N0 invasive NSCLC.
Source: Journal of Thoracic OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The authors present important evidence for clinical applications of selective lymph node dissection strategies in this article, detailing the first prospective trial validating the specific mediastinal LN metastasis pattern in cT1N0 invasive #NSCLC. https://t.co/0p8TqGlRpR #LCSM https://t.co/jkLgpPhCSl
-
The results of this study identify #Pten loss as clinically relevant in driving the molecular and histopatholgical heterogeneity of neuroendocrine (#NE) lung tumors from #adenocarcinoma to #SCLC. https://t.co/KtsUFJMrAd #LCSM https://t.co/s39gvXeazV